Vyriad closes $25M tranche — in‑vivo CAR‑T candidate moves to clinic

Vyriad Inc. closed a $25 million final tranche to its Series B round, bringing total Series B proceeds to $85 million. The financing is earmarked to support first‑in‑human testing of VV‑169, an in‑vivo CAR‑T candidate targeting relapsed or refractory multiple myeloma. The capital raises mirror investor interest in approaches that simplify cell therapies by delivering programming in vivo rather than manufacturing ex vivo CAR‑T products.